

# ACCEPTABILITY AND WILLINGNESS TO SWITCH ANTIRETROVIRAL TREATMENT IN PATIENTS WITH LONG-ACTING INJECTABLE THERAPY CRITERIA

C. SUBIRANA BATLLE<sup>1</sup>, M. BRUGUERA TEIXIDOR<sup>1</sup>, C. ORTÍ JUAN<sup>1</sup>, X. LARREA URTARAN<sup>1</sup>, I. GÓMEZ IBÁÑEZ<sup>1</sup>, Y. ORTUÑO RUIZ<sup>1</sup>, À. CASTELLÓ NÒRIA<sup>1</sup>, L. VIÑAS SAGUÉ<sup>1</sup>, C. DíEZ VALLEJO<sup>1</sup>, E. MARTÍNEZ DÍAZ<sup>1</sup>, A. COUSO CRUZ<sup>1</sup>

<sup>1</sup>HOSPITAL PHARMACY DEPARTMENT, HOSPITAL TRUETA DE GIRONA (SPAIN)

## Background and importance:

The development of long-acting injectable treatment has become a new treatment strategy that could change the handling of patients with antiretroviral therapy (ART) for HIV infection.

## Aim and objectives:

To know the acceptability and willingness of patients with HIV infection to switch their oral antiretroviral treatment to a long-acting injectable.

## Materials and methods:

**Study population:** all adult patients with an indication for cabotegravir/rilpivirine.

**Questionnaire:** patient's data, degree of satisfaction with current treatment and acceptance of the therapy with long-acting injectables.

## Results:




40 men

17 women

57 patients

Median age: 54 years [28-78]



## Conclusion and relevance:

Great acceptability and willingness of our patients to receive long-acting antiretrovirals.

Patients also appreciated being asked their opinion about the treatment.

